All HIV-positive TB patients, with immediate effect, are initiated on ART, irrespective of CD4 count.

Health workers are combining emerging mobile health technologies with community participation to combat tuberculosis in India, which is home to 25 percent of the world's patients of the debilitating disease.

Download the information from here.

Tuberculosis is an old foe. A 500,000-year-old human fossil discovered in Turkey bears telltale signs of the disease, which today continues to wreak havoc, killing an estimated 2 million per year, according to the World Health Organization.

Prison health care in Africa is under-resourced, and increased funding is needed to ensure adequate treatment is available, including anti-retroviral (ART) therapy as treatment for HIV, and for HIV and TB prevention.

Immune reconstitution inflammatory syndrome (IRIS) proved a frequent complication in tuberculosis patients starting antiretroviral therapy (ART) in north India. Meningitis was a common component of TB-IRIS and was often fatal.

May 31 is World No Tobacco Day.

TuBerculosis Vaccine Initiative (TBVI), a non-profit organisation that supports the development of urgently needed new vaccines against tuberculosis (TB), will receive a new grant from the Bill & Melinda Gates Foundation. With the award of up to 3 million dollars spread over 3 years, TBVI can support the development of several TB vaccine candidates and contribute to the fight against this ghastly disease.

A rapid point-of-care breath test accurately detected active pulmonary tuberculosis, according to a report published in the journal "Tuberculosis." Menssana Research developed the breath test in Newark, NJ and was funded by the National Institutes of Health and the US Air Force.

The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.